Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
When an OpenAI agent quietly slipped into an Australian government health portal without permission, it showed how quickly artificial intelligence can move from theory to real life. That same power is now being applied to medical scans, treatment decisions and hospital admin. Investors watching Australian AI healthcare stocks are seeing a new frontier form. This article walks through three screened ideas that bring that theme into clear focus. The three stocks in this piece are just a sample,...
Artrya has recently attracted increased investor attention for its Salix platform, which applies AI to cardiac CT scans to help detect coronary artery disease, with ongoing efforts in clinical validation, regulatory clearances and US market expansion now in focus. This interest highlights how progress in turning Salix into a clinically validated, AI-driven tool that US healthcare providers routinely adopt could be central to Artrya’s longer term commercialisation plans. We’ll now examine how...
As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.